Senti Bio announces U.S. FDA granted ODD to SENTI-202

Senti Bio (SNTI)sciences announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML. Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences commented, “SENTI-202 continues to demonstrate encouraging promise as a potential treatment option for relapsed/refractory AML, an indication with significant unmet need and a dismal median survival rate of 5.3 months3. Receiving Orphan Drug Designation for SENTI-202 provides further validation to our novel approach to overcoming AML heterogeneity and protecting healthy cells, and underscores the need for new and effective treatment options. Building upon our recently reported positive preliminary results, this important milestone bolsters our commitment to advancing the development of this important program forward.”